ADCSOTIO Biotech licenses ADCs from Lonza subsidiary Synaffix BVLatest NewsSotio hsd licenced Synaffix ADC platform for up to US$740m to develop up to three next generation bioconjugates. Read more 16 October 2023 https://european-biotechnology.com/wp-content/uploads/2024/04/Synaffix.jpeg 1024 633 Thomas Gabrielczyk /wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png Thomas Gabrielczyk2023-10-16 06:16:002024-07-09 13:11:05SOTIO Biotech licenses ADCs from Lonza subsidiary Synaffix BV